Moderators: gotinearly , Bigfootbud , pumper_stumper , Carter , Huggy Bear , joe botts
Search This Board: 
Created: 09/03/2014 10:04:29 AM - Followers: 1113 - Board type: Free - Posts Today: 1

Picture

Regen BioPharma 
 

 0.000x  Ticker Symbol: RGBP 

Barchart



All other Regen BioPharma News
https://www.regenbiopharmainc.com/company-news.html




 
 

Regen BioPharma, Inc. 4700 Spring Street, Suite 304
La Mesa, CA 91942 U.S.A.


Telephone: (619) 702-1404
Fax: (619) 330-2328




Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).






 

Product Pipeline | Regen BioPharma, Inc.

Small Molecules Targeting Cancer and Autoimmunity

Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.
  • Objective is to identify small molecules that can activate and inhibit NR2F6
    ?Currently in pre-clinical development 
    Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
    Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
    Additional indications include solid tumors, acute leukemia and GVHD
 

HemaXellerate

Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
  • Fat stem cell based product to treat bone marrow that has been damaged
    Bone marrow damage occurs from radiation, chemo, or chronic conditions
    HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow 
    ?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)



     

dCellVax 

Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
  • 10 advanced breast cancer patients
    Efficacy endpoints at 6 and 12 months
    Establishment of safety will allow for rapid expansion of patient numbers 
    Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program 


     

DiffronC

Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
  • siRNA silencing of our newly discovered cancer stem cell target gene
    Silencing using DiffronC induces differentiation of cancer cells 
    Initial indication is treatment of myelodysplastic syndrome 
    Other indications include solid tumors and acute leukemia



     

Telomeres & Genomic Integrity

Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
  • Telomeres are protective structures at the ends of chromosomes that enable cell divisions
    Telomere attrition is involved in aging, cancer and genetic mutations 
    We are developing drugs that modulate telomere maintenance 
    In pre-clinical development for indications of solid cancers and acute leukemia



     
 

 

RGBP Corporate Debt as of June 30, 2022 (latest published financials)

Current News

 
On July 19, 2022 Regen Biopharma, Inc. (the “Company”) issued 54,514,492 common shares (“Shares”) to Coventry Enterprises LLC in satisfaction of $180,552 of convertible indebtedness. The principal balance and accrued interest payable remaining on the $1,500,000 promissory note issued to Coventry Enterprises LLC are both $0 as of July 19,2022
 


Lately, there seems to be a lot of gross misunderstanding, with claims that the company has no debt.   This is false, period.  If you see some of the discussion, it only focuses on one debt that was paid.  There is no question that is true, but these same discussions somehow ignore the many other debts.   From the most recent financials filed by the company, this is the list of RGBP's current debt.   

ALL OF THE DEBT BELOW IS BESIDES THE COVENTRY DEBT.   NO ONE IS CLAIMING the Conventry DEBT IS NOT PAID OFF!



 Information on debt still in existance is copied below from the most recent financials signed by the CEO:  https://www.otcmarkets.com/filing/html?id=15961397&guid=Kq9-kHnONOQ_h3h

 
As of June 30,2022 the Company has the following Notes  (DEBT) Outstanding

On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.
As of June 30, 2022 $100,000 of the principal amount of the Note remains outstanding.

On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.
As of June 30, 2022 $50,000 of the principal amount of the Note remains outstanding.

According to RGBP, there is also another Note (debt) issued on the same day, for the same amount (not a duplication)

On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.
As of June 20, 2022 $50,000 of the principal amount of the Note remains outstanding.

On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.
As of June 30, 2022 $50,000 of the principal amount of the Note remains outstanding.

March 13, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is February 24, 2020.
As of June 30, 2022 $50,000 of the principal amount of the Note remains outstanding.

On March 31, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 31, 2020.
As of June 30, 2022 $50,000 of the principal amount of the Note remains outstanding.

 On April 19, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is April 19, 2020.
As of June 30, 2022 $50,000 of the principal amount of the Note remains outstanding.

On May 5, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $200,000 for consideration consisting of $200,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is May 5, 2020.
As of June 30, 2022 $200,000 of the principal amount of the Note remains outstanding.

On June 26, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $150,000 for consideration consisting of $150,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is June 16, 2020. 
As of June 30, 2022 $150,000 of the principal amount of the Note remains outstanding.

On September 25, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is September 25, 2020.
As of June 30, 2022 $50,000 of the principal amount of the Note remains outstanding.

On October 3, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 3, 2020
As of June 30, 2022, $50,000 of the principal amount of the Note remains outstanding.


On October 16, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 9, 2020. 
As of June 30, 2022 $100,000 of the principal amount of the Note remains outstanding.

On November 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is November 1, 2020.
As of June 30, 2022 $25,000 of the principal amount of the Note remains outstanding.

On November 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is November 1, 2020. 
As of June 30 2022 $25,000 of the principal amount of the Note remains outstanding.

On December 20, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is December 20, 2020.
As of June 30, 2022 $100,000 of the principal amount of the Note remains outstanding.

On February 28, 2018 (“Issue date”) the Company issued a two Convertible Notes (“Notes”) in the aggregate face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Notes is February 28, 2021. 
As of June 30, 2022 $100,000 of the principal amount of the Notes remains outstanding.

On July 11, 2018 the Company issued a Convertible Note (“Note”) in the face amount of $11,500 to an entity controlled by the Company’s then Chief Financial Officer for consideration consisting of $11,500 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is May 4, 2021.
As of June 30, 2022 $11,500 of the principal amount of the Note remains outstanding.

On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date
As of June 30, 2022, 10,000 of the principal amount of the Note remains outstanding.


 

On July 19, 2019 the Company issued a convertible promissory note in the face amount of $100,000 (“Note”) for consideration consisting of:  $95,000 cash  the payment of $5,000 of legal fees   The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is July 19, 2020

As of June 30, 2022 $1,000 of the principal amount of the Note remains outstanding.


 
 
 
 
 
   
 





Share Dilution History
 
 
Date
Outsanding Shares
4/7/22 4,736,002,832
5/16/22 4,820,002,832
7/1/22 4,920,002,832
   
   
   
   



2022 Updates RGBP FAQ

1)  Q: I've seen claims that RGBP has a product or products currently in Phase 1 or Phase 2 testing.  Is this true?
A:  Not a single document singed by the company, nor a single PR released by the company mentions ANY current FDA approved lab doing any Phase 1 or Phase 2 testing for RGBP.   This will be updated, as soon as either of those are provided!   Note, "clearance" is not testing.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#113492
Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary loophole lawyer 09/13/2022 07:25:15 PM
#113227
reposting off LLY msg board RGBP Is A FAR StocktonCA 09/07/2022 12:57:50 PM
#106600
1 BILLION new shares authorized, necessary, due to pumper_stumper 04/03/2022 09:39:30 PM
#113889
Retail will race to sell..when corp. mms.. say so... moondogaz 09/24/2022 11:53:16 PM
#113888
What's funny? retail $s.. squat. " hold my moondogaz 09/24/2022 11:51:12 PM
#113887
Brother...you know the same things I know.. I moondogaz 09/24/2022 10:36:53 PM
#113886
Your right.. wish I can post publicly what moondogaz 09/24/2022 10:35:00 PM
#113885
Yep, mRNA is here to stay and works SidVicious 09/24/2022 09:08:53 PM
#113884
That’s the perfect definition of Fudpucker Nakedshort and 29YEARINVESTOR 09/24/2022 08:35:12 PM
#113883
lots of wishful thinking and articles written by SidVicious 09/24/2022 07:33:15 PM
#113882
Buyout speculation 29YEARINVESTOR 09/24/2022 06:50:46 PM
#113881
I'm reading the mrna landscape,clear as day..the time moondogaz 09/24/2022 04:05:37 PM
#113880
If that is the case, then why hasn’t SidVicious 09/24/2022 02:21:12 PM
#113879
No matter... He's in the right space,at the moondogaz 09/24/2022 02:17:22 PM
#113878
Koos is no Tesla nor Edison. He is SidVicious 09/24/2022 02:15:09 PM
#113877
Disruptive technology is what built America... When something moondogaz 09/24/2022 01:02:12 PM
#113876
I'm more about the synthetic bio-engineering aid.... It's moondogaz 09/24/2022 12:27:17 PM
#113875
Continue to enjoy the Koos Kool aid. I SidVicious 09/24/2022 12:01:46 PM
#113874
If it makes you feel better..your right on moondogaz 09/24/2022 11:25:17 AM
#113873
LOL! There is nothing REAL about Regen other SidVicious 09/24/2022 10:56:27 AM
#113872
MY MOM DID NOT DIE IN VEIN. ba moondogaz 09/24/2022 12:07:26 AM
#113871
LET IT BE UNDERSTOOD.. CANCER WILL BE NO MORE... moondogaz 09/24/2022 12:06:23 AM
#113870
CANCER WILL BE DESTROYED... moondogaz 09/24/2022 12:04:37 AM
#113869
PEEPS OF RGBP... I NEVER SLEEP.. NITE.... moondogaz 09/24/2022 12:03:52 AM
#113868
" IM ALWAYS RIGHT" nite to all RGBP...INVESTORS... moondogaz 09/23/2022 11:30:46 PM
#113867
mRNA.. is not garbage..IMO. ITS THE FUTURE..OF TREATING moondogaz 09/23/2022 11:29:12 PM
#113866
Simply..good night... moondogaz 09/23/2022 10:58:48 PM
#113865
REAL BUYS .AND REAL SALES.GIVE REAL PROFITS.FOR REAL moondogaz 09/23/2022 10:57:25 PM
#113864
MAYBE...SLEEP WELL.DREAM BIG.... moondogaz 09/23/2022 10:53:23 PM
#113863
Understood...... joe botts 09/23/2022 09:33:36 PM
#113862
Green nice.. BDEZ 09/23/2022 07:47:09 PM
#113861
Just as suspected RGBP Nakedshorted over 60% Today 29YEARINVESTOR 09/23/2022 07:46:02 PM
#113860
LoL the buys and sells are shown in 29YEARINVESTOR 09/23/2022 07:38:47 PM
#113859
LET IT BE UNDERSTOOD THAT FAKE BUYS AND pumper_stumper 09/23/2022 07:01:09 PM
#113858
Let it be Understood those who played 29YEARINVESTOR 09/23/2022 05:41:20 PM
#113857
No matter how sliced/ mrna is here to stay.... moondogaz 09/23/2022 05:36:00 PM
#113856
Your right...but $$$$$...trump's everything.... moondogaz 09/23/2022 05:19:54 PM
#113855
So smart!!!! joe botts 09/23/2022 05:19:41 PM
#113854
Let it be Understood a 92% decline from 29YEARINVESTOR 09/23/2022 05:07:37 PM
#113853
Still no copper! Can't even get over .007 SidVicious 09/23/2022 04:54:32 PM
#113852
I was not aware that Radio said TV SidVicious 09/23/2022 04:51:59 PM
#113851
Radio said that about tv...how did that work out..... moondogaz 09/23/2022 04:49:47 PM
#113850
mRNA is garabage. Pfizer/Moderna are killing people with SidVicious 09/23/2022 04:38:26 PM
#113848
RGBP - STRONG buys into the close. Up mperfection 09/23/2022 04:01:34 PM
#113847
For Regen and Koos, that's for sure. He SidVicious 09/23/2022 02:57:59 PM
#113846
Gonna get much uglier. moondogaz 09/23/2022 02:31:02 PM
#113845
Into "stone" can't squeeze blood out of stone..... moondogaz 09/23/2022 02:30:00 PM
#113844
Objective is to bleed retail,bone dry... moondogaz 09/23/2022 02:22:59 PM
#113843
Let It Be Understood RGBG is down 92% pumper_stumper 09/23/2022 02:22:03 PM
#113842
Shorting is across all indices.. no safe havens... moondogaz 09/23/2022 02:20:12 PM
#113841
Let It Be Understood RGBP Nakedshorted 29YEARINVESTOR 09/23/2022 02:15:00 PM
#113840
100% wrong.. moondogaz 09/23/2022 02:06:51 PM
#113838
Let it be understood that the trading of SidVicious 09/23/2022 12:20:13 PM
Post Subject